|

Anti-PD1 Monoclonal Antibody Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-PD-1 Monoclonal Antibody

Pipeline

Phase 2: 1

Top Sponsors

  • Yuanquan Yang1

Indications

  • Hematopoietic and Lymphatic System Neoplasm1
  • Advanced Malignant Solid Neoplasm1
  • Cancer1

Columbus, Ohio1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.